Onvansertib Emerging Drug Insight

“Onvansertib Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Onvansertib for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the Onvansertib for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Onvansertib for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Onvansertib market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

Onvansertib (also known as NMS-1286937 and PCM-075) is a first-in-class, third-generation, oral, and highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like kinase 1 (PLK1) enzyme, which is over-expressed in multiple cancers, including leukemia, lymphomas, and solid tumors. Onvansertib targets the PLK1 isoform only (not PLK2 or PLK3) and has a 24-hour half-life with only mild-to-moderate side effects reported. It is believed that targeting only PLK1 and having a favorable safety and tolerability profile, along with an improved dose and scheduling regimen, will significantly improve the outcome observed in previous studies with a former pan-PLK inhibitor in AML.

Bevacizumab acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in the microvascular growth of tumor blood vessels and thus limits the blood supply to tumor tissues.

Currently, onvansertib in combination with bevacizumab (VEGF inhibitor) and chemotherapy is being investigated in a Phase II (NCT05593328) and a Phase I/II (NCT03829410) trial for the second-line treatment of metastatic colorectal cancer patients with a KRAS mutation.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Onvansertib description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on Onvansertib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Onvansertib research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Onvansertib.
• The report contains forecasted sales of Onvansertib for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for Onvansertib in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Onvansertib Analytical Perspective by DelveInsight

In-depth Onvansertib Market Assessment

This report provides a detailed market assessment of Onvansertib in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

Onvansertib Clinical Assessment

The report provides the clinical trials information of Onvansertib in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Onvansertib dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to Onvansertib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Onvansertib in Metastatic Colorectal Cancer.
• Our in-depth analysis of the forecasted sales data of Onvansertib from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Onvansertib in Metastatic Colorectal Cancer.

Key Questions

• What is the product type, route of administration and mechanism of action of Onvansertib?
• What is the clinical trial status of the study related to Onvansertib in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Onvansertib development?
• What are the key designations that have been granted to Onvansertib for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of Onvansertib for Metastatic Colorectal Cancer?
• What are the forecasted sales of Onvansertib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to Onvansertib for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?